Evidence map›Paper›PMID 36269133›Full record

ArticleActa biochimica et biophysica Sinica2022

An improved cell line-derived xenograft humanized mouse model for evaluation of PD-1/PD-L1 blocker BMS202-induced immune responses in colorectal cancer.

Pengzhao Shang, Liting Yu, Shucheng Cao, Changying Guo, Wanheng Zhang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Targeting alternative splicing in cancer immunotherapy.Frontiers in cell and developmental biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Pengzhao ShangSchool of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
Liting YuDepartment of Pharmacy, Binzhou Medical University, Yantai 264003, China.
Shucheng CaoSchool of Engineering, China Pharmaceutical University, Nanjing 210009, China.
Changying GuoSchool of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
Wanheng ZhangDepartment of Pharmacy, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China.
China Pharmaceutical University · CNBinzhou Medical University · CNFirst Affiliated Hospital of Henan University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The establishment of an

Indexed as

Colorectal NeoplasmsProgrammed Cell Death 1 ReceptorAcetamidesAnimalsB7-H1 AntigenCell Line, TumorDisease Models, AnimalHeterograftsHumansImmunityImmunotherapyMiceMice, Inbred NODPyridinesTumor MicroenvironmentXenograft Model Antitumor AssaysAcetamidesB7-H1 AntigenBMS202Programmed Cell Death 1 ReceptorPyridinesBMS202cancer immunotherapycell-derived xenografthumanized mouse modelPD-1/PD-L1 blocker

Identifiers

PMID36269133
PMCPMC9827804
OpenAlexW4303520567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.